Immuneering Corporation (NASDAQ:IMRX) shares surged 12.5% in after-hours trading Thursday following the release of updated clinical trial data for its pancreatic cancer treatment.
The company reported a 17.3-month median overall survival in first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel in its Phase 2a clinical trial, as of the April 24, 2026 data cutoff date. The data includes 55 patients and will be presented at the American Society of Clinical Oncology Annual Meeting on June 1, 2026.
The trial showed only two categories of Grade 3 or higher treatment-related adverse events in 10% or more of patients: anemia at 16% and neutropenia at 18%, both chemotherapy-related. The company stated the tolerability profile was consistent with prior updates.
Immuneering’s pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in patients with first-line metastatic pancreatic cancer is currently recruiting. The company said it is on track to dose the first patient in mid-2026.
The expanded cohort of 55 first-line patients includes an initial cohort of 34 patients previously reported, plus an additional 21 patients. Full data including details on overall survival, progression free survival, response, safety, weight stability, and other information will be shared in an oral presentation by Peter Vu of UC San Diego Health on June 1, 2026.
The company plans to hold an investor conference call on June 1, 2026, at 8:00 a.m. EST.
